# SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days

Lucas Bochnia-Bueno,[a,c] M.Sc; Sergio Monteiro De Almeida,[a] PhD; Sonia Mara Raboni,[a,c] PhD; Douglas Adamoski,[b] PhD; Ludmilla Louise Moreira Amadeu[a]; Suzana Carstensen;[a] M.Sc, Meri Bordignon Nogueira,[a*] PhD

[a] Virology Laboratory, Federal University of Paraná, General Carneiro, 180, Curitiba, Brazil

[b] Department of Genetics, Federal University of Paraná, Curitiba, PR, Brazil

[c] Post-Graduate Program in Microbiology, Parasitology and Pathology, Federal University of Paraná, Curitiba, PR, Brazil

**#Corresponding author:**

Meri Bordignon Nogueira

R Padre Camargo, 280, Curitiba, Brazil

Zip Code: 80060-240

Phone: +55 41 3360-7974

E-mail: meribordignon.nogueira@gmail.com

**Word counts:** 2,372

**Abstract**

**Background:** This study aimed to calculate the seroconversion rate of the CoronaVac vaccine in healthcare workers (HCWs) 40 days after immunization.

**Methods:** Serum samples from 133 HCWs from Southern Brazil were collected one day before (Day 0) and +10, +20, and +40 days after administering the vaccine's first dose. Immunoglobulin G (IgG) was quantified using immunoassays for anti-N-protein antibodies (Abbott, Sligo, Ireland) and for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany).

**Results:** Seroconversion by day 40 occurred in 129 (97%) HCWs for the S1 protein, and in 69 (51.87%) HCWs for the N protein. An absence of IgG antibodies (by both methodologies), occurred in two (1.5%) HCWs undergoing semiannual rituximab administration, and also in another two (1.5%) HCWs with no apparent reason.

**Conclusion:** This study showed that CoronaVac has a high seroconversion rate when evaluated in an HCW population.

**Funding:** This work was supported by the PROPLAN/Federal University of Paraná, Curitiba-Paraná, Brazil; FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 (0494/20).

**Keywords:** SARS-CoV-2, Vaccine, Immunization, Public health, Immunoglobulin G, CoronaVac, Pandemic.

## 1. Introduction

By June 18, 2021, approximately one year after the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, confirmed cases of infection worldwide numbered 177,108,695 people, including 8,840,223 deaths[1]. After the description of this new human coronavirus in December 2019, there was a global effort by researchers, public and private companies in the search for an effective vaccine to control this pandemic[2–4]. These studies resulted in late 2020, with the first doses of immunization in the population, and there are currently 2,377,780,590 doses of the vaccine administered until June 16, 2021[1].

Many SARS-CoV-2 proteins can induce an immune response, amongst them: M (membrane), E (envelope), N (nucleocapsid), and S (spike)[5]. However, the S and N proteins are the most responsive to infection, which induces high titers of anti-SARS-CoV-2 IgM and IgG antibodies. S protein has been more studied for vaccines because it participates in the virus entry mechanism through the connection of the S1 region receptor-binding domain (S1-RBD) in virus particles with the angiotensin-converting enzyme 2 (ACE 2) in the host cell[6,7]. Then, the antibodies binding in this region can cause viral neutralization. Both S and N proteins have also been used for diagnosis, S protein is more specific despite being a more variable portion. In contrast, N protein is a more preserved region, including high homology with N protein SARS-CoV (> 90%), but both may have false-positive results[8]. To evaluate the neutralization antibody activity, the gold-standard assay is the plaque reduction neutralization test (PRNT) that involves the measurement of the ability of patient sera to prevent infection[9]. However, since this assay is time-consuming and requires higher levels of biological safety, multiple groups proposed anti-RBD ELISA assays as a reliable tool to predict neutralization[9–11].

Worldwide efforts resulted in several vaccines against SARS-CoV-2 with distinct antigen platforms systems (non-replicating viral vector, protein subunit, inactivated virus, and mRNA), with the main antigenic focus on S protein[2,3].

The vaccination in Brazil started with CoronaVac (Sinovac Life Sciences, Beijing, China) in January 2021, and until June 2021, two other vaccines come into use in the country. However, CoronaVac (Sinovac Life Sciences, Beijing, China) remains the most administered in Brazilian territory[12], using the inactivated virus as a component of the vaccine[2,3]. In phase I/II studies, this vaccine was safe, tolerable, presented high immunogenicity, and had uncommon adverse reactions. A similar response was observed for both tested concentrations (3 μg and 6 μg), and 97% of seroconversion occurred in the participants with 18-59 ages[11]. In phase III trials, carried out with health care workers, this vaccine presented 50.7%, 83.7%, and 100% efficacy against symptomatic disease, cases requiring assistance, and severe cases, respectively[13]. Phase III also tested some serum samples against the B.1.1.28, gamma (P.1), and P.2 variants, showing great antibody response[14].

As the vaccine has been administered to people with different ethnicities, comorbidities, and ages, the results of pre-approval clinical trials for its use may not perfectly reflect the response to the vaccine. Thus, vaccine response analyses, either by seroconversion or by neutralizing antibody titration, are essential to assess the possible impacts of this immunization on the population and must be monitored so that the humoral response time can be defined. In this context, this study aimed to identify the seroconversion rate after vaccination with SARS-CoV-2 (CoronaVac) in healthcare workers (HCWs) 40 days after its application.

## 2. Methods

### 2.1 Participants

In total, 170 participants were recruited at the Complexo Hospital de Clínicas, UFPR, Clinical Laboratory, Curitiba, Brazil, during the vaccination of HCWs in this city. The Institutional Ethical Committee approved the study (CAAE: 31687620.2.0000.0096), and all participants signed their consent.

The inclusion criteria were as follows: answering the questionnaire, being vaccinated with two doses of CoronaVac, and providing serum samples. Fourteen participants were excluded because they did not complete the questionnaire. In addition, seven participants took another vaccine, one participant did not have the second dose, and 15 participants did not provide a sample on days 0 (previous vaccination) or +40 (post-vaccination) (Figure 1).

Serum samples of 133 healthcare workers included in this study were collected on days 0 (previous first dose application), +10, +20, and +40 after the first dose. On day 0 and +40, 133 serum samples were analyzed, and on day +10 and +20, 123 and 119 serum samples were analyzed, respectively. All samples were stored at −20 ºC until analysis.

The participants were divided into two groups based on day 0 serology according to anti-spike-1 (anti-S1) immunoglobulin G (IgG)[5,15,16]: *reactive* (n=16) and *non-reactive* (n=117). The participants were also sorted according to the presence of comorbidities into two divisions: *immunosuppressed* (n=9) or *not* (n=124) (Figure 1; Table 1). The immunosuppressed group consisted in participants who presented comorbidity associated with compromised humoral or cellular immune response or those who used immunosuppressive drugs, such as HIV infection, use of chemotherapy or steroids (prednisone at a dose of 20 mg/day or equivalent).

Seroconversion evaluation

Semi-quantitative assays were performed to detect anti-SARS-CoV-2 IgG. For all serum samples, assays used the Chemiluminescent Microparticle Immunoassay (CMIA) Architect-I System for anti-nucleocapsid protein (anti-N) IgG (Abbott, Sligo, Ireland). Additionally, for serum samples from days 0 and +40, assays used the Enzyme-Linked Immunosorbent Assay (EIA) for IgG anti-S1 spike-protein receptor-binding domain (RBD) (Euroimmun, Lübeck, Germany).

Samples were tested in duplicate, following the manufacturer's instructions. Results with a variation coefficient greater than 15.0% were repeated.

2.2 Statistical analysis

According to the distribution of seroconversion at day +40, the category variables were evaluated using Pearson's chi-squared test with Yates' continuity correction. The age variable was evaluated using the Wilcoxon signed rank sum test with continuity correction. Samples paired over time were evaluated using the Friedman ANOVA test (as implemented in the rstatix package), followed by the Wilcoxon signed rank test as a post-hoc pairwise comparison. For samples without multiple observations over time, the Wilcoxon signed rank test was used. All statistical analyses were performed using R (R Core Team).

## 3. Results

3.1 Seroconversion to S1 protein

Robust production of anti-S1-protein IgG was observed by day +40 in 129 (97%) HCW participants (Figure 2B) by the index test result. Although the reactive (Figure 3D) and non-reactive (Figure 3B) groups had different average index values for S1-protein IgG on day 0 ($p < 0.0001$), on day +40, the average index between the groups was not significantly different ($p = 0.3704$).

3.2 Seroconversion to N protein

The dynamics of anti-N-protein IgG for all participants are shown in figure 2A. Distributing the data in the division of groups is possible to observe no significant production of the anti-N-protein IgG in non-reactive group participants 10 days after the first vaccine dose ($p = 0.5027$; Figure 3A), and although there was a statistical difference in the sample on day +20 ($p < 0.0001$), there was no apparent seroconversion at that time. By contrast, there was a marked increase in N-protein IgG levels in 69 (51.87%) participants on day +40 (Figure 3A). A significant difference was also observed in the average index for this antibody between the reactive (Figure 3C) and non-reactive groups (Figure 3A): day 0 ($p < 0.0001$) and day +40 ($p = 0.0657$).

3.3 Combined response

In the non-reactive group, better-developed antibody responses were observed for N and S1 proteins ($p < 0.0001$; Figure 3A, B), while in the reactive group, the antibody response showed a significant difference ($p < 0.0001$) only for antibodies against S1 protein (Figure 3D), increasing the level of circulating humoral response. No significant changes were observed in IgG anti-N protein analysis for the reactive group at days +10, +20, and +40 ($p = 0.2231$). The antibody index for IgG anti-N and anti-S1 presented at day +40 approximated mean of 2.0 and 6.0, respectively.

Comorbidities were reported by some HCWs, including Crohn's disease, prior bariatric surgery, HIV+, or diabetes. In general, the participants with comorbidities responded to the vaccine similarly to participants without any comorbidities. However, two cases in the immunosuppressed group did not undergo seroconversion (Figure 4). Furthermore, two other HCWs (not in the immunosuppressed group) did not seroconvert by day +40; both had no apparent cause. These four HCWs without seroconversion were re-

evaluated by a serum sample taken at +60 days. Of these, one participant presented seroconversion of the S1 protein (Figure 5).

In the anti-S1 reactive group on day 0, six (37.50%) participants did not have a previous SARS-CoV-2 diagnosis, possibly due to asymptomatic infection. Furthermore, in the anti-S1 non-reactive group, 7 (5.98%) participants had symptoms suggestive of SARS-CoV-2 (fever, dry cough, tiredness, loss of taste or smell, aches and pains, headache, sore throat, nasal congestion, red eyes, diarrhea, or a skin rash)[17], although we did not have information about nasopharyngeal RT-PCR or immunological rapid-test detection. Demographic data according to immunologic response and comorbidities, are shown in Table 1.

**Discussion**

The seroconversion rate of 97% for the anti-S1 IgG observed in HCWs is important data and corroborates the results of phase I/II trials of Coronavac vaccine[13]. However, it should be noted that the necessary antibody titers for protection are not entirely known. Furthermore, in the clinical trials carried out previously to vaccine registration, the primary outcome was disease severity, so it cannot be affirmed so far whether seroconversion or antibody titers are associated with protection from infection.

Several mutations in the RBD region of the S1 protein have been shown, giving rise to the viral variants of concern, as previously described: gamma (P.1), P.2, beta (B.1.351), alpha (B.1.1.7), and B.1.325[18–20]. Such mutations confer the potential for the virus to escape the humoral immune response produced due to the disease or to viral vectors or mRNA vaccines[21]. Thus, studies that evaluate vaccine efficacy against these new strains are valuable[22].

Seroconversion rates observed for anti-N protein IgG could be valuable with the emergence of SARS-CoV-2 variants, considering the lower mutation levels in this protein[16], compared to the high mutation levels in the S1 protein[15]. Thus, seroconversion of N-protein antibodies may be an alternative for the vaccine industry to produce efficient vaccines for circulating strains, including those that may arise in the future. However, more studies are needed to understand the impact of antibodies against other viral proteins in the protection against infection.

Curiously, there was no difference in the analysis for the anti-N protein IgG in the reactive group, possibly due to the antibody levels present at day 0 in this group; the vaccine has not interfered in the humoral response; the group remained at the same average index. A total of 5.98% of the participants without seroconversion reported they had been previously infected by SARS-CoV 2. All of them presented seroconversion after the complete vaccination. Moreover, whether the person had experienced the disease or not, the levels of antibodies at day +40 post-vaccine were the same. This finding agrees with Krammer et al.[23] in a study of individuals with and without previous COVID-19, given the mRNA vaccine. This same response level implies the same antigen concentration, showing no difference in individual antibody response regardless of the previous infection.

Higher index of anti-S1 antibodies were observed in comparison to the response of anti-N antibodies, corroborating what was exposed by Jiang et al.[8]. The Khoury et al.[24] determination can be used to estimate the level of neutralizing antibodies; for a 50% protection caused by neutralizing antibodies, approximately 20% of the antibody levels observed in the ELISA assays correspond to this level of protection. And for 50% protection in severe cases, only 3% of antibody levels observed in ELISA assays

correspond to such protection in severe cases [24]. Therefore, it is possible to estimate the index of neutralizing antibodies in this study.

In participants with immunosuppressive treatment (n=2), the absence of the antibody response was probably due to rituximab having been administered approximately one month before the vaccine. In this situation, as described by Kado et al.[25], there is a significant B lymphocytes decrease. Consequently, there is no production of antibodies until the B lymphocytes recover in 6 to 24 months. In such cases, the response must be evaluated after the repletion time, and re-vaccination considered with medical and clinical endorsement. Two other participants did not seroconvert on day +40. One of these had late-response seroconversion on day +60. No explanation was found for the other case, and more studies are needed to understand what interfered with the immune response.

The immune response developed by vaccination depends not just on antibodies but primarily on neutralizing antibodies[26]. Both natural infection and vaccination act on the immune system in complex ways, stimulating the production of non-neutralizing antibodies (with their specific actions) and TCD4+ and TCD8+ T cells, which also act to protect against COVID-19, as shown by Tarke et al.[26]. That study evaluated the immune response to the SARS-CoV-2 variants and showed that cellular immunity-unlike the humoral response, is little affected by the virus variants. In addition to the specific immune response, innate immunity is another essential protection mechanism against infections[26].

The present study has some limitations: the humoral immunity was studied semi-quantitatively, there was no quantification and titration of anti-SARS-CoV-2 antibodies, and no testing for neutralizing antibodies. The total number of participants was small, and immunosuppressed comorbidities were low in number and had diverse etiologies.

More studies are needed to elucidate the vaccine response in these specific groups. However, this is the first study to evaluate the dynamics of IgG anti-N and anti-S1 production after CoronaVac immunization in the community.

The results of seroconversion have shown the importance of two doses for this vaccine as, until the second dose was applied, there was no change in the production of N-protein IgG, as previously described by Zhang et al.[27] in phase I/II tests for this vaccine, with the antibody response detectable just 14 days after the second dose. The second dose is important for several types of vaccines, including mRNA vaccines, as described by Dörschug et al.[28], resulting in a significant increase in antibody levels. Therefore, with SARS-CoV-2, there would be no difference at this point.

In conclusion, significant antibody production was observed 40 days after the first CoronaVac dose in the large majority of study participants, independent of comorbidities. The anti-N protein and anti-S1 protein antibody responses of participants without prior SARS-CoV-2 infection were comparable with those of the previously infected group, in which the immune response was maintained or optimized, with no decrease in levels.

## Acknowledgments

The authors would like to thank all participants who agreed to participate in this study, those involved in the collection and storage of samples, and the Immunochemistry Laboratory section of Complexo Hospital de Clínicas, UFPR, and CAPES.

## Conflict of interest

The authors declare that there is no conflict.

## References

1. World Health Organization (WHO), WHO Coronavirus (COVID-19) Dashboard. [cited 2021 Jun 24] Available from: https://covid19.who.int/

2. Golob JL, Lugogo N, Lauring AS, Lok AS. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021 Apr 6;

3. Kumar SU, Priya NM, Priyanka SRN, Nikita K, Thirumal JD. A review of novel coronavirus disease ( COVID ꟷ 19 ): based on genomic structure , phylogeny , current shreds of evidence , candidate vaccines , and drug repurposing. 3 Biotech. 2021;

4. Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. SARS-CoV-2 vaccines: Lights and shadows. Eur J Intern Med [Internet]. 2021 Jun 8;88(March):1–8. Available from: https://doi.org/10.1016/j.ejim.2021.04.019

5. Zeng W, Liu G, Ma H, Zhao D, Yang Y, Liu M, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527(3):618–23.

6. Barchuk A, Shirokov D, Sergeeva M, Tursun-zade R, Dudkina O, Tychkova V, et al. Evaluation of the performance of SARS-CoV--2 antibody assays for the longitudinal population-based study of COVID-19 spread in St. Petersburg, Russia. J Med Virol. 2021;

7. Saelens X, Schepens B. Single-domain antibodies make a difference. Science (80- ). 2021;371(6530):681–2.

8. Jiang H wei, Li Y, Zhang H nan, Wang W, Yang X, Qi H, et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020;11(1):1–11.

9.    Murray MJ, McIntosh M, Atkinson C, Mahungu T, Wright E, Chatterton W, et al. Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay. J Infect. 2021;82(5):170–7.

10.    Papenburg J, Cheng MP, Corsini R, Caya C, Mendoza E, Manguiat K, et al. Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. Open Forum Infect Dis. 2021;8(6).

11.    Padoan A, Bonfante F, Cosma C, Di Chiara C, Sciacovelli L, Pagliari M, et al. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: Comparison with neutralization titers. Clin Chem Lab Med. 2021;1–23.

12.    Brasil, Ministério da Saúde, COVID-19 Vacinação Doses Aplicadas. [cited 2021 Jun 24] Available from: https://viz.saude.gov.br/extensions/DEMAS_C19Vacina/DEMAS_C19Vacina.html

13.    Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis [Internet]. 2021 Feb;21(2):181–92. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309920308434

14.    Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos J do P, Tilli Reis Pessoa Conde M, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN Electron J

[Internet]. 2021; Available from: https://www.ssrn.com/abstract=3822780

15.    Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Front Immunol. 2021;12(March):1–12.

16.    Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. J Virol. 2020;94(13):1–2.

17.    World Health Organization (WHO), Coronavirus disease (COVID-19) advice for the public. [cited 2021 Jun 24] Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public

18.    Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet [Internet]. 2021 Feb;397(10273):452–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673621001835

19.    Claro IM, da Silva Sales FC, Ramundo MS, Candido DS, Silva CAM, de Jesus JG, et al. Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020. Emerg Infect Dis [Internet]. 2021 Mar;27(3):970–2. Available from: https://wwwnc.cdc.gov/eid/article/27/3/21-0038_article.htm

20.    Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020;2.

21.    Garcia-beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced

humoral immunity. medRxiv. 2021;

22. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885–98.

23. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med [Internet]. 2021 Apr 8;384(14):1372–4. Available from: http://www.nejm.org/doi/10.1056/NEJMc2101667

24. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med [Internet]. 2021; Available from: http://dx.doi.org/10.1038/s41591-021-01377-8

25. Kado R, Sanders G, Joseph McCune W. Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol. 2016;28(3):251–8.

26. Tarke A, Sidney J, Methot N, Zhang Y, Dan JM, Goodwin B, et al. Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv Prepr Serv Biol [Internet]. 2021; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33688655%0Ahttp://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=PMC7941626

27. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged

18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical

trial. Lancet Infect Dis. 2021;21(2):181–92.

28.   Dörschug A, Frickmann H, Schwanbeck J, Yilmaz E, Mese K, Hahn A, et al.

Comparative Assessment of Sera from Individuals after S-Gene RNA-Based

SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based

Serological Assays. Diagnostics. 2021;11(3):426.

**Figure 1**: Participants included and excluded in the study and division of groups for analysis. Comorbidities (immunosuppressive) included: Immunosuppressive drugs use, Crohn's disease, bariatric surgery, HIV and Diabetes.

**Figure 2**: Dynamics of antibody response after vaccine application. The line connecting the dots represents the humoral curve for each participant included in the study. The dotted line represents the days of the vaccine application (two doses). **A** - N-protein IgG evaluation in all participants. **B** - S1-protein IgG evaluation in all participants

**Figure 3**: Antibody rates in the S1-protein IgG seroconverted/not seroconverted groups at day 0. Boxplot graph presents median (line dividing the box), interquartile range (box), maximum value (line above the box), and minimum value (line below the box). The line connecting the boxes represents the trend of the data. The dotted line represents the days of the vaccine application (two doses). **A** - N-protein IgG evaluation in S1-antibody nonreactive participants at day 0. **B** - S1-protein IgG evaluation in S1-protein IgG nonreactive participants at day 0. **C** - N-protein IgG evaluation in S1-protein IgG reactive participants at day 0. **D** - IgG anti-S1 protein evaluation in anti-S1 protein IgG reactive participants at day 0.

**Figure 4**: Antibody rates for participants with and without immunosuppression. White boxes indicate non-immunosuppressed participants. Gray boxes indicate immunosuppressed participants. **A** - S1-protein IgG evaluation. **B** - N-protein IgG evaluation.

**Figure 5**: Antibody rates for participants without seroconversion on day +40. Purple and green lines represent the participants with Rituximab treatment. The dotted line

represents the days of the vaccine application (two doses). **A** - N-protein IgG evaluation. **B** - S1-protein IgG evaluation.

**Table 1**: Demographics characteristics of participants included in the study for each respective group. Information on the handling of special cases: two immunosuppressed (Rituximab 1400 mg/semiannually), one myasthenia gravis (Pyridostigmine 120 mg/day), one Crohn's disease ostomized twenty-two years ago (Azathioprine 100 mg/day), two participants with bariatric surgery (11 and 12 years), and one HIV+ (Tenofovir 300 mg, Lamivudine 300 mg + Dolutegravir 50 mg/day; $CD4^+$ 541/µL). *Comorbidities (immunosuppressive) included: Immunosuppressive drugs use, Crohn's disease, bariatric surgery, HIV and Diabetes. The patient with Myasthenia gravis is not included here because the treatment used was not immunosuppressive.

Table 1:

| | IgG Anti-S1 (Day 0) | | | Comorbidities immunosuppressive* | | |
|---|---|---|---|---|---|---|
| | Reactive n (%) | Non-reactive n (%) | p value | With n (%) | Without n (%) | p value |
| Total | 16 | 117 | | 9 | 124 | |
| Female | 13 (81.25) | 93 (79.49) | 1.0000 | 6 (66.67) | 100 (80.64) | 0.5636 |
| Median Age (IQR) | 44 (25.25 -52.75) | 49 (39.50 - 53.50) | 0.2225 | 51 (45.50 - 54.50) | 48 (38.25 - 53.75) | 0.2297 |

# Without IgG anti-S1 at day 0

**A**

Friedman ANOVA *p* < 0.0001

*p* < 0.0001

*p* < 0.0001

*p* < 0.0001

*p* < 0.0001

*p* = 0.5027

Anti-N-protein assay index

0    +10    +20    +40

Sample day

**B**

*p* < 0.0001

Anti-S1-protein assay index

0    +10    +20    +40

Sample day

# With IgG anti-S1 at day 0

**C**

Friedman ANOVA *p* = 0.2231

Anti-N-protein assay index

0    +10    +20    +40

Sample day

**D**

*p* < 0.0001

Anti-S1-protein assay index

0    +10    +20    +40

Sample day